Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Maximilian Merz; Hans Salwender; Mathias Haenel; Elias K. Mai; Uta Bertsch; Christina Kunz; Thomas Hielscher; Igor W. Blau; Christof Scheid; Dirk Hose; Anja Seckinger; Anna Jauch; Jens Hillengass; Marc S. Raab; Baerbel Schurich; Markus Munder; Peter Brossart; Christian Gerecke; Hans Walter Lindemann; Matthias Zeis; Katja Weisel; Jan Duerig; Hartmut Goldschmidt

Article

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Haematologica

DOI: 10.3324/haematol.2016.151266

11Citations

21Readers

Get full text

Cite

CITATION STYLE

APA

Merz, M., Salwender, H., Haenel, M., Mai, E. K., Bertsch, U., Kunz, C., … Goldschmidt, H. (2016). Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica. Ferrata Storti Foundation. https://doi.org/10.3324/haematol.2016.151266

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial

Cite

Register to see more suggestions